TWiV 895: COVID-19 clinical update #112 with Dr. Daniel Griffin

<p>In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.</p> <p>Subscribe (free): <a title= "http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?id=300973784" href= "https://podcasts.apple.com/us/podcast/this-week-in-virology/id1176779065">Apple Podcasts</a>, <a href= "https://www.google.com/podcasts?feed=aHR0cDovL3R3aXYubWljcm9iZXdvcmxkLmxpYnN5bnByby5jb20vdHdpdg%3D%3D">Google Podcasts</a>, <a href= "http://twiv.microbeworld.libsynpro.com/twiv">RSS</a>, <a href="http://eepurl.com/Gcw59">email</a></p> <p>Become a <a href= "https://www.microbe.tv/contribute">patron</a> of TWiV!</p> <h3 id="links-for-this-episode"><strong>Links for this episode</strong></h3> <ul> <li>Seroprevalence of <a href= "https://www.cdc.gov/mmwr/volumes/71/wr/mm7117e3.htm?s_cid=mm7117e3_e&ACSTrackingID=USCDC_921-DM80513&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2071%2C%20April%2026%2C%202022&deliveryName=USCDC_921-DM80513">Infection-Induced Antibodies</a> (CDC) </li> <li><a href= "https://investors.modernatx.com/news/news-details/2022/Moderna-Files-for-Authorization-of-Its-COVID-19-Vaccine-in-Young-Children-Six-Months-to-Under-Six-Years-of-Age/default.aspx"> Authorization for Vaccine</a> in Young Children Filed (Moderna)</li> <li><a href= "https://www.bmj.com/content/377/bmj-2021-069317">Public Health Impact</a> of Vaccines in US (BMJ)</li> <li>FDA authorizes first <a href= "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children">approved treatment for children</a> (FDA)</li> <li><a href= "https://verupharma.com/news/veru-announces-oral-late-breaking-presentation-of-phase-2-data-of-sabizabulin-for-the-treatment-of-hospitalized-severe-covid-19-patients-at-high-risk-for-acute-respiratory-dis